Curis traded at $1.05 this Wednesday August 17th, decreasing $0.01 or 0.94 percent since the previous trading session. Looking back, over the last four weeks, Curis lost 9.48 percent. Over the last 12 months, its price fell by 85.58 percent. Looking ahead, we forecast Curis to be priced at 1.12 by the end of this quarter and at 1.03 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,864.00 20.00 0.52% 5.20%
Amgen 248.98 -1.60 -0.64% 9.76%
AstraZeneca 11,026.00 24.00 0.22% 26.21%
Bayer 53.76 0.39 0.73% 12.83%
Bristol-Myers Squibb 74.41 -0.15 -0.20% 8.61%
Chimerix 2.55 -0.13 -4.85% -57.85%
Curis 1.05 -0.01 -0.94% -85.58%
Exelixis 18.92 -0.39 -2.02% 3.61%
Gilead Sciences 65.37 -0.65 -0.98% -8.79%
GlaxoSmithKline 1,415.00 -0.40 -0.03% -6.51%
Incyte Corp 73.16 -0.70 -0.95% -1.85%
Eli Lilly 316.31 -0.51 -0.16% 16.98%
Merck & Co 91.17 0.13 0.14% 17.20%
Mirati Therapeutics 78.28 -1.94 -2.42% -43.56%
Novartis 81.35 0.12 0.15% -4.75%
Pfizer 49.01 -0.26 -0.53% -0.61%
Roche Holding 319.10 2.45 0.77% -14.22%
Sanofi 81.38 -0.29 -0.36% -9.75%
Spectrum Pharmaceuticals 1.23 -0.18 -12.77% -44.34%
TG Therapeutics 7.43 -0.35 -4.50% -66.61%
Verastem 1.30 -0.07 -5.11% -50.00%
Xoma 17.85 -0.15 -0.83% -32.92%
Ziopharm Oncology 1.85 0 0% 11.45%

Indexes Price Day Year
USND 12911 -27.38 -0.21% -11.22%

Curis
Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program.